Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04476043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
August 25, 2020
Completion date
August 16, 2023
Enrollment
209 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

acne inversa, hidradenitis suppurativa